We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+7.28%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$781M
AUM Growth
+$281M
Cap. Flow
+$296M
Cap. Flow %
37.86%
Top 10 Hldgs %
66.38%
Holding
71
New
25
Increased
8
Reduced
8
Closed
25

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$123M
2
NKTX icon
Nkarta
NKTX
+$60.3M
3
KROS icon
Keros Therapeutics
KROS
+$47.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$45.4M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$41.8M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$31.2M
2
BNTX icon
BioNTech
BNTX
+$19.7M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$16.9M
4
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$16.7M
5
AKBA icon
Akebia Therapeutics
AKBA
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FULC icon
51
Fulcrum Therapeutics
FULC
$241M
– –
-410,000
Closed -$7.5M
GBIO
52
DELISTED
Generation Bio
GBIO
– –
-32,500
Closed -$6.83M
IGMS
53
DELISTED
IGM Biosciences
IGMS
– –
-91,841
Closed -$6.7M
IMVT icon
54
Immunovant
IMVT
$7.93B
– –
-625,000
Closed -$15.2M
MREO
55
Mereo BioPharma
MREO
$48.9M
– –
-200,000
Closed -$612K
PCVX icon
56
Vaxcyte
PCVX
$7.65B
– –
-455,000
Closed -$14.4M
RCKT icon
57
Rocket Pharmaceuticals
RCKT
$343M
– –
-150,000
Closed -$3.14M
STRO icon
58
Sutro Biopharma
STRO
$386M
– –
-36,195
Closed -$2.81M
SWTX
59
DELISTED
SpringWorks Therapeutics
SWTX
– –
-110,000
Closed -$4.62M
XFOR icon
60
X4 Pharmaceuticals
XFOR
$377M
– –
-5,283
Closed -$1.48M
LUMO
61
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-50,000
Closed -$825K
FUSN
62
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-121,128
Closed -$2.12M
AMTI
63
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
– –
-664,186
Closed -$16.7M
RETA
64
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-200,000
Closed -$31.2M
ISEE
65
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-900,000
Closed -$4.59M
BLU
66
DELISTED
BELLUS Health Inc.
BLU
– –
-600,000
Closed -$6.17M
APTO
67
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-1,667
Closed -$4.73M
OBSV
68
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-1,165,000
Closed -$6.86M
ARNA
69
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-268,500
Closed -$16.9M
PRNB
70
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-150,000
Closed -$8.97M
ZGNX
71
DELISTED
Zogenix, Inc.
ZGNX
– –
-400,000
Closed -$10.8M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q3 2020 Portfolio in Review

As of Q3 2020, Logos Global Management held 71 positions worth $781M, up 56% from $500M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Logos Global Management deployed $296M of net new capital in Q3 2020, opening 25 new positions and adding to 8 existing holdings. Its largest new stake was ALX Oncology: 3,136,981 shares worth $118M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Celldex Therapeutics, an estimated $9.37M trimmed.

  • Logos Global Management's largest Q3 2020 buy was ALX Oncology: 3,136,981 shares worth $118M.
  • Logos Global Management added most to Keros Therapeutics in Q3 2020, an estimated $47.6M increase.
  • Logos Global Management's biggest Q3 2020 reduction was Celldex Therapeutics, cutting an estimated $9.37M.
  • Logos Global Management fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020, selling an estimated $31.2M.
  • Logos Global Management's ten largest holdings make up 66% of its $781M portfolio in Q3 2020.
  • Logos Global Management opened 25 new positions and closed 25 in Q3 2020.
  • Logos Global Management's portfolio value rose 56% quarter-over-quarter to $781M.

Based on Logos Global Management's 13F filing for Q3 2020, filed 16 Nov 2020.